ECE2018 Poster Presentations: Diabetes, Obesity and Metabolism Diabetes therapy (43 abstracts)
Cognitive status, anxiety and depression in patients with type 2 diabetes mellitus on selective DPP4 inhibitor therapy
Marina Nikolic Djurovic 1 , Zvezdana Jemuovic 1 , Olga Vasovic 2 , Sandra Pekic 1 , Dragana Miljic 1 , Marko Stojanovic 1 , Biljana Salak Djokic 3 , Gordana Krljanac 4 & Milan Petakov 1
1Clinic for Endocrinology, Diabetes and Diseases of Metabolism, University Clinical Center, Belgrade, Serbia; 2Institute for Gerontology and Palliative Care, Belgrade, Serbia; 3Clinic for Neurology, University Clinical Center, Belgrade, Serbia; 4Clinic for Cardiology, University Clinical Center, Belgrade, Serbia.
Introduction: Cognitive functions and mood (anxiety and depression) are often impaired in diabetes mellitus (DM). Dipeptidyl peptidase-4 inhibitor (DPP-4) has been shown to exert beneficial effects on insulin sensitivity and glycoregulation in T2DM patients. Introducing DPP-4 therapy leads to maintaining control of glucose levels which could ameliorate or slow down further cognitive and mood disorders impairment.
Aim: To evaluate influence of selective DPP-4 inhibitor therapy on cognitive functions, anxiety and depression in T2DM patients.
Method: This was controlled, prospective randomized study with 40 patients with T2DM patients on metformin therapy (63.3±7.4 yrs) and 34 healthy subjects (63.6±6 yrs) matched for age, gender and education. In all subjects, glycemia and Hba1c levels were measured before and six months after DPP-4 inhibitor therapy was introduced. Neuropsychological testing included MMSE, verbal and visual attention span, Trail Making tests A and B (TMTA, TMTB), Test for verbal divergent thinking–phonemic and category fluency (FF and CF), Hospital anxiety and depression scale.
Results: Glycemic control was statistically significantly improved after 6 months in 2DM group (Hba1c 8.32±1.4 vs 7.35±1.19, P<0.001). Some aspects of executive functions (TMTA, TMTB, visual span) were better after 6 months like (TMTA 52.45±20.98 vs 48.00±18.84, P=0.014, TMTB 96.06±26.08 vs 87.91±29.14, P=0.003, visual span 4.18±0.80 vs 4.64±0.90, P=0.009) as well as level of depression (HADSD 5.23±3.83 vs 4.27±3.03, P=0.009).
Conclusion: Improvement in cognitive functions and depression in T2DM patients after 6 months on DPP-4 inhibitor therapy were confirmed. Further clinical studies with longer follow up period are necessary to elucidate our findings.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more